Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an announcement.
Livzon Pharmaceutical Group Inc. announced the election of Ms. Wang Zhiyao as an Independent Non-Executive Director and Ms. Ran Yongmei as an Employee Representative Director to its eleventh session of the Board. These appointments strengthen the company’s governance structure, ensuring compliance with regulatory requirements and enhancing representation within the board. The inclusion of Ms. Wang and Ms. Ran is expected to bring diverse perspectives and expertise, potentially impacting the company’s strategic direction and stakeholder engagement positively.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development, production, and distribution of pharmaceutical products. The company is known for its innovative healthcare solutions and has a significant market presence in China.
Average Trading Volume: 860,760
Technical Sentiment Signal: Hold
Current Market Cap: HK$33.01B
For detailed information about 1513 stock, go to TipRanks’ Stock Analysis page.